The largest shareholder of well-known pharmaceutical company Yuheng Pharmaceuticals files for bankruptcy

Pharmaceutical Network July 9th - How the future yuheng Pharmaceuticals can save its performance, after the largest controlling shareholder enters bankruptcy reorganization proceedings, or for a difficult question1
, Yuheng Pharmaceuticals controlling shareholders, to go bankrupt?On July 6, YuHeng Pharmaceuticals issued a notice that Yuheng Group's creditors applied to the Harbin Intermediate People's Court of Heilongjiang Province for bankruptcy reorganization of Yuheng Group on the grounds that Yuheng Group was unable to pay off its maturing debts and the assets were not sufficient to pay off all its debtsThe Harbin Intermediate People's Court of Heilongjiang Province accepted the case and ruled as follows: Acceptthement of the bankruptcy reorganization application of Yu Heng Group's creditors against Yu Heng GroupGuizhou Xinbang Pharmaceuticals also said that it received a notice from the controlling shareholder, Tibet YuyuVentureInvestment Co., Ltd("Tibet Reputation" ) and one of the co-action vehicles Harbin Yuheng Group Co., Ltd(hereinafter referred to as "Yu Heng Group"), the success of the bankruptcy reorganization of Yuheng Group is uncertain, in addition, whether the actual control of the company is also uncertainThe data show that in our country, the beginning of bankruptcy proceedings is not based on the application, but on the acceptanceThus, an insolvency application is not a sign of the commenceation of insolvency proceedings, but rather a condition for the commenceation of insolvency proceedingsIn this regard, Saber blue consulted the legal community related people, the other side said: the court to accept the bankruptcy reorganization application, does not mean thatenterprisewill be bankrupt, because reorganization is? Reorganizing your business? It means that if someone takes over and the debt is fully liquidated, it is successfully restructured and can not enter into bankruptcy proceedings; otherwise, the people's court will decide and declare the enterprise bankrupt according to law, and the enterprise will enter into bankruptcy proceedings, and the people's court shall set up a liquidation group on the 15th from the date of the declaration to take over the bankrupt enterpriseBut the above-mentioned people admitted: filing for bankruptcy reorganization, means that the enterprise does have a lot of business difficulties and credibility problemsCyber Blue in the enterprise check official website query learned that for Yuheng Pharmaceuticals, Harbin Yuheng Group holding a large share of up to 37.39%, the highest proportion of shares held 　　And Saber Blue query found that the actual controller of YuHeng Group is Zhu Jiman, shareholders have four people, for Zhu Jiman, Bai Lihui, Wang Dongxu, Yang Hongbing, legal person for Bai Lihui 　　It is worth noting that the actual controller of Yuheng Pharmaceuticals is also Zhu Jiman, Bai Lihui, if YuHeng Group formally bankrupt, will also bring a greater impact on Yuheng Pharmaceuticals 　　The announcement shows that there is uncertainty as to the success of the bankruptcy reorganization of the company's controlling shareholder, Yu Heng Group, and whether it will lead to changes in the company's control 　　Yu Heng Pharmaceuticals said that the company and YuHeng Group in the assets, business, financial and other aspects of the independent, Yuheng Group into bankruptcy reorganization proceedings will not affect the normal operation of the company Up to now, the company's production and operation situation is normal 　　2
, Yuheng Pharmaceuticals, the performance of consecutive years of losses
Yuheng Pharmaceuticals 2019 annual report shows that the company's net profit loss during the reporting period as high as 2.662 billion yuan, down 2214 percent year-on-year Net profit in the first half of this year was "big flip", with profit selling more than 600 million yuan, up 171.22 percent to 192.75 percent year-on-year 　　Yuheng Pharmaceuticals said the increase in the company's results from a year earlier was mainly due to the impact of non-recurring gains and losses, mainly due to the company's confirmation of the related gains from the sale of 100 per cent of Aono Pharmaceuticals Excluding the above factors, affected by the outbreak of new crown pneumonia, the company and the industry upstream and downstream delayed resumption of work, personnel, logistics constraints, product demand decline, the first half of this year is expected to show a significant decline in the same period last year 　　Because of the debt default, Yuheng Group's stake in Yuheng Pharmaceuticals has been auctioned several times, which also has a certain impact on Yuheng Pharmaceuticals 　　Financial data show that Yuheng Pharmaceuticals went public in 2010, but its performance has been declining since 2016 The company's net profit growth for 2014-2018 was 156.65 percent, 53.72 percent, 6.27 percent, -60.11 percent, and -99.61 percent, respectively, with a huge loss in 2019 and a net profit after deducting -2596 million yuan 　　mergers and acquisitions, or one of the reasons 　　It is understood that the company's own research and development strength is weak, through mergers and acquisitions to expand their own product lines, products are mainly through acquisitions, technology transfer, exclusive agent and other ways to obtain The company initially to the home-grown products of deer melon peptide injection as the leading, and supplemented by a number of agent varieties In recent years, the company through a series of technology transfer and acquisition, the product line gradually enriched, with an brain pill, sodium phosphonate, Ginkgo ester B injection and other heavy varieties 　　At the same time, the industry believes that the crazy mergers and acquisitions are the main reason for the decline in performance Since its listing in 2010, the company has proposed large-scale extended mergers and acquisitions, no less than 21 transactions, transactions amounting to more than 10 billion yuan, forming a huge goodwill value 　　Starting in 2018, the shares of the controlling shareholders and co-action holders of Yuheng Pharmaceuticals have been regularly frozen/waiting for a judicial freeze, the company's debt crisis has continued, and the company's repeated restructuring failures have led to a fall in the share price, according to Eeer Financial As a result of the fall in the share price, the controlling shareholder and the co-action holder pledged shares were closed 　　How to save performance in the future, after the controlling shareholders entered the bankruptcy reorganization proceedings, or for a difficult problem